GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Praxsyn Corp (GREY:PXYN) » Definitions » Debt-to-EBITDA

Praxsyn (Praxsyn) Debt-to-EBITDA : 0.17 (As of Sep. 2015)


View and export this data going back to 2007. Start your Free Trial

What is Praxsyn Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Praxsyn's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $3.41 Mil. Praxsyn's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.17 Mil. Praxsyn's annualized EBITDA for the quarter that ended in Sep. 2015 was $21.72 Mil. Praxsyn's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 was 0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Praxsyn's Debt-to-EBITDA or its related term are showing as below:

PXYN's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.66
* Ranked among companies with meaningful Debt-to-EBITDA only.

Praxsyn Debt-to-EBITDA Historical Data

The historical data trend for Praxsyn's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxsyn Debt-to-EBITDA Chart

Praxsyn Annual Data
Trend Oct05 Oct06 Oct07 Oct08 Oct09 Dec10 Dec11 Dec12 Dec13 Dec14
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.05 -1.63 1.91 0.21

Praxsyn Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -0.46 0.19 0.16 0.17

Competitive Comparison of Praxsyn's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Praxsyn's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Praxsyn's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Praxsyn's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Praxsyn's Debt-to-EBITDA falls into.



Praxsyn Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Praxsyn's Debt-to-EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.876 + 0.227) / 19.18
=0.21

Praxsyn's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.406 + 0.168) / 21.716
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2015) EBITDA data.


Praxsyn  (GREY:PXYN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Praxsyn Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Praxsyn's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Praxsyn (Praxsyn) Business Description

Traded in Other Exchanges
N/A
Address
61 Spectrum Boulevard, Suite A, Las Vegas, NV, USA, 89101
Praxsyn Corp is a healthcare company, dedicated to providing medical practitioners with medications and services for their patients. Through its retail pharmacy facility, it formulates healthcare practitioner-prescribed medications to serve patients who experience chronic pain. It primarily focuses on non-narcotic and non-habit forming medications using therapeutic and preventative agents for pain management. In addition, the group prepares innovative products that address erectile dysfunction and metabolic issues and other ancillary products. The products of the firm are either picked up directly from pharmacy facility or shipped directly to patients. The business activities are functioned through the regions of United States.

Praxsyn (Praxsyn) Headlines